ESAB Corporation (ESAB) Stock Price & Analysis
ESAB Corporation (ESAB) closed at USD 66.89 on Thursday, October 22, 2026, up 0.80% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 66.36; the Oct 22, 2026 session ranged USD 63.81–67.09 on volume of 848,970 shares. Market capitalization is $4.16B, with a 52-week range of USD 62.74–137.42 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 08:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ESAB.md
Key facts (ESAB)
- Last four reported quarters (through Jul 3, 2026): revenue $3.00B, net income $173M (5.7% margin), free cash flow $197M (SEC filings).
- Valuation: P/E 24.1x (avg 27.8x at the last 3 fiscal year-ends), EV/EBITDA 13.7x, net debt $2.18B.
- 1 of 80 tracked superinvestors hold ESAB (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $95K; 1 not under a Rule 10b5-1 plan ($95K); 1 by opportunistic insiders (1 outside 10b5-1 plans), 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (11 analysts), mean target USD 119.73 (range 95–145).
- Total return with dividends: 1Y -45.5% vs S&P 500 +14.9%; 5Y +36.1% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 1.33, revenue estimate $787M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ESAB)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.43B | $2.59B | $2.77B | $2.74B | $2.84B | $3.00B |
| Gross profit | $838M | $886M | $1.02B | $1.04B | $1.05B | — |
| Operating income | $306M | $329M | $404M | $447M | $412M | $362M |
| Net income | $235M | $224M | $205M | $265M | $227M | $173M |
| EPS (diluted) | $3.92 | $3.69 | $3.36 | $4.31 | $3.67 | — |
| Free cash flow | $215M | $174M | $282M | $304M | $213M | $197M |
| Gross margin | 34.5% | 34.1% | 36.6% | 37.9% | 36.9% | — |
| Operating margin | 12.6% | 12.7% | 14.6% | 16.3% | 14.5% | 12.1% |
| Net margin | 9.7% | 8.6% | 7.4% | 9.7% | 8.0% | 5.7% |
| Revenue growth | +24.5% | +6.8% | +7.0% | -1.2% | +3.7% | — |
| Cash + short-term investments | $41.2M | $72.0M | $102M | $249M | $186M | — |
| Total debt | $0K | $1.22B | $1.02B | $1.08B | $1.23B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 3, 2026) (ESAB)
P/E 24.1x · P/S 1.4x · EV/EBITDA 13.7x · EV/Sales 2.1x · P/FCF 21.1x · P/B 1.6x · FCF yield 4.73% · Earnings yield 4.15% · Dividend yield (paid, TTM) 0.59% · Net debt $2.18B · EV $6.34B
P/E at fiscal year-ends: Dec 2025 30.2x, Dec 2024 27.7x, Dec 2023 25.6x.
Superinvestors (SEC 13F-HR, Q2 2026) (ESAB)
1 of 80 tracked investors hold ESAB. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $5.1M | New position |
Insider sales (SEC Form 4, open-market, last ~7 months) (ESAB)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-07 | Jordan Rhonda L | Director | 1,000 | $95K | 10.7% | No | Opportunistic (traded every year 2023–2025, no repeating month) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (ESAB)
Consensus Buy (mean 2.00 on a 1–5 scale), 11 analysts; mean target USD 119.73 (low 95, high 145).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Oppenheimer | Target lowered | Outperform | $135 → $110 |
| 2026-10-08 | JP Morgan | Target lowered | Overweight | $125 → $95 |
| 2026-09-15 | Roth Capital | Target lowered | Buy | $151 → $133 |
| 2026-08-11 | Evercore ISI Group | Target lowered | In-Line | $103 → $100 |
| 2026-07-21 | Oppenheimer | Target lowered | Outperform | $140 → $135 |
| 2026-07-20 | Stifel | Target lowered | Buy | $141 → $137 |
| 2026-07-07 | Roth Capital | Target raised | Buy | $142 → $151 |
Total return (dividends reinvested) (ESAB)
| 1Y (from 2025-10-23) | 5Y (from 2022-03-28) | |
|---|---|---|
| Total return | -45.5% | +36.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -45.6% | +7.0% |
| Volatility (annualized) | 46.1% | 36.5% |
| Max drawdown | -52.0% (Feb 2026→Oct 2026) | -51.7% (Feb 2026→Sep 2026) |
ESAB revenue by business segment (quarter ended Jul 3, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| EMEA & APAC | $491.7M | 60.9% | +13.6% |
| Americas | $315.9M | 39.1% | +11.7% |
| Total revenue | $807.6M | 100% | — |
ESAB revenue by product line (quarter ended Jul 3, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Consumables | $494.6M | 61.2% | +2.3% |
| Equipment | $313.0M | 38.8% | +35.0% |
| Total revenue | $807.6M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
ESAB company outlook (results filed Aug 6, 2026)
- “ESAB has updated its full-year 2026 outlook, which now projects total core sales growth of 11.0% to 14.0%, an increase from the previous guidance of 6.0% to 9.0%.”
- “Within this growth, core organic sales remains 2.0% to 4.0%, while the contribution from M&A has been revised upward to approximately 9.0% from 4.0%, and the anticipated FX impact has remained the same with the prior range of 0.0% to 1.0%.”
- “Consequently, the company has raised its core adjusted EBITDA forecast to a range of $615 million to $625 million, up from the previous $575 million to $595 million, while the outlook for core adjusted EPS has been adjusted to a range of $5.40 to $5.50.”
Quoted word-for-word from the SEC 8-K results press release.
ESAB analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.33 | $1.47 | -9.6% | $786.7M | 10 |
| Next quarter (ends Dec 2026) | $1.42 | $1.53 | -7.4% | $782.8M | 10 |
| Current fiscal year (ends Dec 2026) | $5.39 | $5.70 | -5.5% | $3.06B | 11 |
| Next fiscal year (ends Dec 2027) | $6.38 | $6.67 | -4.3% | $3.34B | 11 |
ESAB options: expected move
Options price a move of about ±13.5% (±$9.00) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±4% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 62.2% | ±13.5% |
| Dec 18, 2026 | 56 | 50.0% | ±15.6% |
| Jan 15, 2027 | 84 | 49.3% | ±18.7% |
| Apr 16, 2027 | 175 | 48.3% | ±26.2% |
30-day implied volatility 58.3% vs 46.6% realized over the last 30 trading days. Put/call ratio (volume) 10. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 08:39 UTC)
| Price | USD 66.89 |
|---|---|
| Change | ▲ 0.80% (up) |
| Previous Close | USD 66.36 |
| Open | USD 64.79 |
| Day Range | USD 63.81 – 67.09 |
| 52-Week Range | USD 62.74 – 137.42 |
| Volume | 848,970 shares |
| Market Cap | $4.16B |
| Exchange | NYQ |
Technical Analysis (ESAB)
Nexqual's technical model rates ESAB "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 08:39 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 45.37 (neutral) |
| vs SMA50 | Below (USD 71.5) |
| MACD | -1.64 (negative) |
Analyst Ratings (ESAB)
Wall Street analysts rate ESAB "Buy" based on 11 analysts, with a mean price target of USD 119.73 (range USD 95–145), per Nexqual as of October 23, 2026 at 08:39 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 119.73 |
| High Target | USD 145 |
| Low Target | USD 95 |
| Buy / Hold / Sell | 10 / 1 / 0 |
Earnings (ESAB)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 1.33 |
| Revenue Estimate | $786.67M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.33 vs est 1.37 ▼ miss |
| 2026-03-31 | USD 1.31 vs est 1.34 ▼ miss |
| 2025-12-31 | USD 1.35 vs est 1.34 ▲ beat |
| 2025-09-30 | USD 1.32 vs est 1.27 ▲ beat |
Source: Nexqual, October 23, 2026 at 08:39 UTC.
Financials & Fundamentals (ESAB)
| Total Revenue | $3.00B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +12.90% |
| Gross Margin | +36.96% |
| Operating Margin | +12.02% |
| Profit Margin | +5.75% |
| ROE | +8.73% |
| Debt / Equity | 0.98 |
| Current Ratio | 1.96 |
| Total Cash | $217.49M |
| Total Debt | $2.54B |
| Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K) | $196.61M (6.5% of revenue) |
Source: Nexqual, October 23, 2026 at 08:39 UTC.
Financial Health Score (ESAB)
Nexqual rates ESAB Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 08:39 UTC.
| Growth | Mixed — Revenue +4.2% YoY (annual), slow |
|---|---|
| Profitability | Solid — Gross margin 37%, operating 12% (last 12 months) |
| Balance Sheet | Mixed — $217M cash and investments vs $2.40B debt (Jul 2026, SEC) |
| Cash Flow | Solid — FCF $197M (last 4 quarters to Jul 2026, SEC), 7% margin |
| Efficiency | Mixed — ROE 9%, ROA 5.0% |
Ownership (ESAB)
| Insider Ownership | +6.49% |
|---|---|
| Institutional Ownership | +103.78% |
| Shares Outstanding | 62.14M |
| Float | 58.07M |
| Short % of Float | +10.26% |
Source: Nexqual, October 23, 2026 at 08:39 UTC.
Leadership (ESAB)
ESAB Corporation is led by Shyam P. Kambeyanda, President, CEO & Director, per Nexqual as of October 23, 2026 at 08:39 UTC.
| President, CEO & Director | Shyam P. Kambeyanda |
|---|---|
| Executive Chairman of the Board | Mitchell P. Rales |
| Executive VP & CFO | R. Brent Jones |
| Vice President of Investor Relations | Mark Barbalato |
| Vice President of Corporate Communications | Tilea Coleman |
Major Backers & Investors (ESAB)
Notable institutional backers of ESAB Corporation include Price (T.Rowe) Associates Inc, T. Rowe Price, Invesco, according to Nexqual as of October 23, 2026 at 08:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 13.07% |
| T. Rowe Price | 12.26% |
| Invesco | 4.46% |
| FIL LTD | 3.77% |
| Cooke & Bieler LP | 3.54% |
| Capital Group | 3% |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 3% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.55% |
| Vanguard Group | 8.18% |
| State Street | 2.93% |
Source: Nexqual, October 23, 2026 at 08:39 UTC.
From ESAB Corporation's Latest SEC 10-K Filing (filed 2026-02-20)
Legal & Regulatory Risks (Item 1A, quoted)
- We have done and may continue to do business in countries subject to United States sanctions. Failure to comply with various sanction laws may result in enforcement or other regulatory actions.
- Our efforts to comply with United States and other applicable sanction laws may not be effective, and consequently, we may face enforcement or other actions if our compliance efforts are not or are perceived as not being wholly effective.
- We are subject to a variety of increasingly stringent environmental and health and safety laws for which compliance, or related liabilities, could be costly.
- The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GPGI | GPGI, Inc. | USD 12.55 | ▼ 2.86% |
| WOR | Worthington Enterprises, Inc. | USD 64.44 | ▼ 1.01% |
| CMC | Commercial Metals Company | USD 63.79 | ▼ 0.72% |
| PRLB | Proto Labs, Inc. | USD 84.36 | ▼ 5.94% |
| RYZ | Ryerson Holding Corporation | USD 28.05 | ▼ 0.28% |
| MLI | Mueller Industries, Inc. | USD 54.53 | ▼ 5.23% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 08:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt